“The period 2005 to 2009 will see the expiration of patent protection for 39 major drugs in the United States, an average of 8 a year. With 2004 seeing a decline in the number of NCEs approved down to 23 from 27 in 2003, there is clear evidence that the loss of revenue from patent protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market.”
Once patent protection and periods of marketing exclusivity expire for a branded drug, sales tend to decline dramatically as generic substitutes capture market share.
Patent expiration for a major product can see revenues for the supplier fall ten-fold within two years. The loss of patent protection for key products is increasingly significant in assessing the future performance of major pharmaceutical companies. The decline of revenues to generic substitutes has a major influence on the financial performance of such companies. Conversely, the successful identification and exploitation of the opportunities afforded by patent expirations provides a major growth driver for the pharmaceutical companies who focus their business on the provision of generic therapeutics.
With this background, Urch Publishing has commissioned a study into the effect of patent expiries on some of the major branded pharmaceutical products.
Generic Competition to 2009 provides the concise and accurate overview of forthcoming generic competition.
Key features of this report
Reviews of over 40 major drugs that will come off patent btweeen 2005 and 2006
Listing of generic regulatory filing activity
Solid overview of market for generic drugs over the next four years
Global product sales figures for years 2000-2004 with share by company revenue & market segment
Remember! The increasing use of generic therapeutics, which combine high volumes with low prices, has led generics to capture 14% of the global healthcare market in 2004, with overall revenues of $58 billion. The imminent patent expirations of many major drugs, 42 in the period 2005 to 2009 in major markets, will provide a major growth stimulus for the generics companies as they compete to capture market share from multi-billion dollar drugs whose patents expire in this period.
You have been warned!
Additional Information
Use this report to:
Forecast the market share that will be lost to generic competition
Understand which global companies are under pressure from generics
Consider the effect of expiry on the patent holder’s competitors
See whether there are any outstanding litigation issues
Learn which generic companies are active in filing
(0 items)
